Zelira Therapeutics (ASX:ZLD )

  • Symbol:ASX:ZLD
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Richard Hopkins
  • Founded:2003
Categories:

Zelira Therapeutics (ASX:ZLD ) Stock Price

Disclaimer: Past performance is not an indicator of future performance.

Zelira Therapeutics (ASX:ZLD ) Company Overview

Formerly known as Zelda Therapeutics, Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company focused on developing a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

Zelira Therapeutics was formed through a merger of equals between Zelda and Ilera Therapeutics, who both went on to become Zelira Therapeutics LLC in late 2019.

Under the new name Zelira, the merged companies fused to create a global cannabis company with operations in Australia and the US, bringing together a portfolio of revenue-generating medicines and products that are expected to enter the market from 2020.

Zelira Therapeutics' stated goal is to build a portfolio of clinically-validated assets (typically cannabinoid-derived formulas) to treat a wide range of diseases. In pursuing this goal, Zelira has formed a series of strategic partnerships throughout Australia and abroad.

Zelira will be undertaking human clinical trials focused on insomnia, autism and opioid reduction with activities in Australia and the USA, as well as pre-clinical research that will examine the effect of cannabinoids in breast, brain and pancreatic cancer as well as the potential for cannabinoids to treat diabetes-associated cognitive decline.

Through the newly merged company, Zelira Therapeutics would also have access to Ilera's HOPE range of medicinal cannabis products, which will be acquired as part of the merger. Following news of the announcement, ZLD stock was up as much as 7.5% to 8.6 cents.

Prior to the merger, Zelda Therapeutics had already entered into an agreement with SUDA Pharmaceuticals Ltd (ASX: SUD) to develop novel oral spray formulations that would effectively deliver the company's pharmaceutical-grade cannabis medicines. Furthermore, the company has established a series of partnerships to open up distribution channels throughout Europe, the US and Australia.

 

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.